Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis

Figure 2

Network diagrams of available treatment comparisons for each outcome. The size of the nodes is proportional to the number of patients (in parentheses) randomized to each treatment, and the width of the lines is proportional to the number of trials (beside the line) comparing the connected treatments. C indicates chemotherapy; CL, chemotherapy plus lapatinib; CP, chemotherapy plus pertuzumab; CT, chemotherapy plus trastuzumab; CTL, chemotherapy plus trastuzumab plus lapatinib; CTP, chemotherapy plus trastuzumab plus pertuzumab; MP, trastuzumab emtansine plus pertuzumab; TP, trastuzumab plus pertuzumab.

(a) Pathologically complete response. 3868 patients and 2422 events (16 trials)

(b) Serious adverse events. 3306 patients and 1066 events (11 trials)

(c) Breast-conserving surgery rate. 3086 patients and 1706 events (11 trials)